Storia in 2 fonti

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Gilead Sciences (NASDAQ:GILD)

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.

Raccontata da

fiercepharma.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 mesi fa

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Gilead Sciences (NASDAQ:GILD)

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.

originale

fiercepharma.com3 mesi fa

Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population

Livdelzi met phase 3 primary endpoint in PBC, expanding use to UDCA-intolerant patients showing normalized alkaline phosphatase levels. $133M Q1 2026 sales (3.3× YoY) validates Gilead's $4.3B CymaBay acquisition and market position vs Iqirvo in rare hepatic disease.

Leggi questa versione →

Timeline cronologica

martedì 2 giugno 2026·fiercepharma.com
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint,
martedì 2 giugno 2026·benzinga.com
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Gilead Sciences (NASDAQ:GILD)
Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.